PatentJun 2, 2026, 05:17 PM
Heron CINVANTI Patents Invalidated by District Court Decision
AI Summary
Heron Therapeutics announced that the U.S. District Court for the District of Delaware issued a decision on June 1, 2026, holding that asserted claims of its U.S. Patent Nos. 12,115,255 and 12,290,520, which cover CINVANTI, are invalid. This ruling follows a patent infringement complaint filed by Heron against Slayback Pharma (now Azurity Pharmaceuticals) in response to Slayback's NDA for a generic CINVANTI. Heron intends to appeal the decision to the United States Court of Appeals for the Federal Circuit, and the decision has no impact on any prior settlement agreements related to CINVANTI or APONVIE®.
Key Highlights
- District Court ruled Heron's U.S. Patent Nos. 12,115,255 and 12,290,520 for CINVANTI invalid.
- Decision issued on June 1, 2026, following a bench trial against Azurity Pharmaceuticals.
- Heron intends to appeal the decision to the U.S. Court of Appeals for the Federal Circuit.
- The ruling does not affect prior settlement agreements for CINVANTI or APONVIE®.
- The lawsuit originated from a Paragraph IV notice from Slayback Pharma in December 2023.
Price Impact
More from HRTX